British pharmaceutical group GSK has announced a definitive agreement to acquire US-based RAPT Therapeutics, a company focused on developing therapies for inflammatory and immunological diseases, according to Forbes. The transaction values RAPT Therapeutics at approximately USD 2.2 billion and marks GSK’s entry into the food allergy treatment segment.
The acquisition brings ozureprubart into GSK’s pipeline, a long-acting anti-immunoglobulin E (IgE) monoclonal antibody currently in Phase IIb clinical development. The drug is designed as a prophylactic therapy to protect against food allergens and could allow dosing intervals of around 12 weeks, compared with current treatments that require injections every two to four weeks.
Read also: Eli Lilly becomes the first drugmaker in the world to reach a $1 trillion market valuation
Company data show that around 94% of severe food allergies are IgE-mediated. In the United States, more than 17 million people are diagnosed with food allergies, while over 1.3 million experience severe reactions, leading to more than 3 million hospital and emergency room visits each year.
GSK estimates that ozureprubart could also address the needs of around 25% of patients who are not eligible for existing therapies. Final Phase IIb data are expected in 2027, with Phase III trials planned for both adult and pediatric populations.
“Adding ozureprubart brings a potential best-in-class treatment into our portfolio. Food allergies have a major impact on patients, and current therapies require frequent injections. A 12-week dosing regimen could significantly change disease management,” said Tony Wood, GSK’s Chief Scientific Officer.
Under the terms of the deal, GSK will pay RAPT Therapeutics shareholders USD 58 per share, implying an equity value of approximately USD 2.2 billion. After accounting for cash acquired, GSK’s net upfront investment is estimated at USD 1.9 billion. The transaction strengthens GSK’s respiratory, immunology, and inflammation portfolio, a key strategic growth area for the company.
Photo: European CEO
